AU2016352943B2 - Improved TNF binders - Google Patents

Improved TNF binders Download PDF

Info

Publication number: AU2016352943B2
Authority: AU; Australia
Prior art keywords: ser; gly; val; thr; arg
Prior art date: 2015-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

AU2016352943A

Other languages

English (en)

Other versions

AU2016352943A1 (en

Inventor

Joachim Boucneau

Marie-Ange Buyse

Peter Casteels

Gino Van Heeke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ablynx NV

Original Assignee

Ablynx NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-14

Publication date

2022-10-20

2016-11-14 Application filed by Ablynx NV filed Critical Ablynx NV

2018-06-07 Publication of AU2016352943A1 publication Critical patent/AU2016352943A1/en

2022-10-20 Application granted granted Critical

2022-10-20 Publication of AU2016352943B2 publication Critical patent/AU2016352943B2/en

2023-01-10 Priority to AU2023200113A priority Critical patent/AU2023200113A1/en

Status Active legal-status Critical Current

2036-11-14 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Organic Insulating Materials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)

AU2016352943A 2015-11-12 2016-11-14 Improved TNF binders Active AU2016352943B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2023200113A AU2023200113A1 (en)	2015-11-12	2023-01-10	Improved TNF binders

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562254375P	2015-11-12	2015-11-12
US62/254,375		2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en)	2015-11-12	2016-11-14	Improved tnf binders

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2023200113A Division AU2023200113A1 (en)	2015-11-12	2023-01-10	Improved TNF binders

Publications (2)

Publication Number	Publication Date
AU2016352943A1 AU2016352943A1 (en)	2018-06-07
AU2016352943B2 true AU2016352943B2 (en)	2022-10-20

Family

ID=57348648

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2016352943A Active AU2016352943B2 (en)	2015-11-12	2016-11-14	Improved TNF binders
AU2023200113A Pending AU2023200113A1 (en)	2015-11-12	2023-01-10	Improved TNF binders

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2023200113A Pending AU2023200113A1 (en)	2015-11-12	2023-01-10	Improved TNF binders

Country Status (37)

Country	Link
US (2)	US10544211B2 (2)
EP (2)	EP3191511B1 (2)
JP (2)	JP6962915B2 (2)
KR (2)	KR20240029115A (2)
CN (1)	CN108473563B (2)
AU (2)	AU2016352943B2 (2)
BR (1)	BR112018009714A8 (2)
CA (2)	CA3005085C (2)
CL (1)	CL2018001291A1 (2)
CO (1)	CO2018005915A2 (2)
CR (1)	CR20180311A (2)
CY (1)	CY1120303T1 (2)
DK (1)	DK3191511T3 (2)
DO (1)	DOP2018000122A (2)
EC (1)	ECSP18042569A (2)
ES (1)	ES2662418T3 (2)
GT (1)	GT201800095A (2)
HK (1)	HK1248716A1 (2)
HR (1)	HRP20171949T1 (2)
HU (1)	HUE035805T2 (2)
IL (2)	IL259269B2 (2)
LT (1)	LT3191511T (2)
MA (1)	MA41653A (2)
MD (1)	MD3191511T2 (2)
ME (1)	ME02954B (2)
MX (1)	MX385207B (2)
NO (1)	NO2768984T3 (2)
PE (1)	PE20181317A1 (2)
PH (1)	PH12018501025A1 (2)
PL (1)	PL3191511T3 (2)
PT (1)	PT3191511T (2)
RS (1)	RS56676B1 (2)
SG (1)	SG11201803975SA (2)
SI (1)	SI3191511T1 (2)
SM (1)	SMT201700590T1 (2)
TN (1)	TN2018000159A1 (2)
WO (1)	WO2017081320A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en)	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4707303A2 (en)	2014-05-16	2026-03-11	Ablynx NV	Improved immunoglobulin variable domains
IL318433A (en)	2014-05-16	2025-03-01	Ablynx Nv	Improved immunoglobulin variable complexes
NO2768984T3 (2) *	2015-11-12	2018-06-09
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
IL293561A (en)	2019-12-06	2022-08-01	Ablynx Nv	Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
KR20220111313A (ko)	2019-12-06	2022-08-09	아블린쓰 엔.브이.	TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
CN112300289B (zh) *	2019-12-30	2022-06-10	中国药科大学	RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
EP4263602A1 (en)	2020-12-18	2023-10-25	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
US20250026842A1 (en) *	2021-11-29	2025-01-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Modified protein or polypeptide
AU2023373192A1 (en) *	2022-11-04	2025-04-17	St. Jude Children's Research Hospital, Inc.	Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
AR131494A1 (es)	2022-12-23	2025-03-26	Ablynx Nv	Vehículos de conjugación a base de proteína
TW202448926A (zh)	2023-02-17	2024-12-16	比利時商艾伯霖克斯公司	結合新生兒fc受體之多肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006122786A2 (en) *	2005-05-18	2006-11-23	Ablynx Nv	Improved nanobodies™ against tumor necrosis factor-alpha
WO2015173325A2 (en) *	2014-05-16	2015-11-19	Ablynx Nv	Improved immunoglobulin variable domains

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1621554T4 (da)	1992-08-21	2012-12-17	Univ Bruxelles	Immunoglobuliner blottet for lette kæder
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da)	1997-10-27	2010-05-10	Bac Ip Bv	Multivalente antigenbindende proteiner
KR20010034512A (ko)	1998-02-19	2001-04-25	베렌슨, 론	림프구 활성화 조절을 위한 조성물 및 그 방법
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004041863A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
EP1900753B1 (en) *	2002-11-08	2017-08-09	Ablynx N.V.	Method of administering therapeutic polypeptides, and polypeptides therefor
JP2006517789A (ja)	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE602004017726D1 (de)	2003-06-30	2008-12-24	Domantis Ltd	Pegylierte Single-domain-antikörper (dAb)
ATE485307T1 (de)	2003-11-07	2010-11-15	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es)	2004-12-02	2008-03-04	Domantis Ltd	Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
ES2694247T3 (es)	2005-05-20	2018-12-19	Ablynx N.V.	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
DE102005023617A1 (de) *	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
ES2626610T3 (es)	2005-08-30	2017-07-25	Intrexon Actobiotics Nv	Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
JP2009519011A (ja)	2005-12-01	2009-05-14	ドマンティスリミテッド	インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
EA200801166A1 (ru)	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
US20100047171A1 (en)	2006-01-24	2010-02-25	Roland Beckmann	Fusion Proteins That Contain Natural Junctions
WO2008020079A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20080267949A1 (en)	2006-12-05	2008-10-30	Ablynx N.V.	Peptides capable of binding to serum proteins
CA2687903C (en)	2007-05-24	2016-09-13	Ablynx N.V.	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2650311A3 (en)	2007-11-27	2014-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2285833B1 (en)	2008-05-16	2014-12-17	Ablynx N.V.	AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AU2010215479B2 (en) *	2009-02-19	2015-01-22	Glaxo Group Limited	Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
NZ595461A (en)	2009-04-10	2013-01-25	Ablynx Nv	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2011006915A2 (en)	2009-07-16	2011-01-20	Glaxo Group Limited	Improved anti-serum albumin binding single variable domains
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
CN103917560B (zh)	2011-03-28	2017-05-24	埃博灵克斯股份有限公司	双特异性抗‑cxcr7免疫球蛋白单可变结构域
SG10201805064SA (en) *	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en)	2011-06-23	2019-09-11	Ablynx NV	Serum albumin binding proteins
PE20141522A1 (es) *	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
NO2768984T3 (2) *	2015-11-12	2018-06-09
JP7540877B2 (ja) *	2016-02-12	2024-08-27	アブリンクスエン．ヴェー．	免疫グロブリン単一可変ドメインの生成方法

2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active IP Right Grant
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/it unknown
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Pending
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active Active
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 MX MX2018005992A patent/MX385207B/es unknown
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
2018
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006122786A2 (en) *	2005-05-18	2006-11-23	Ablynx Nv	Improved nanobodies™ against tumor necrosis factor-alpha
WO2015173325A2 (en) *	2014-05-16	2015-11-19	Ablynx Nv	Improved immunoglobulin variable domains

Also Published As

Publication number	Publication date
AU2023200113A1 (en)	2023-02-16
PH12018501025A1 (en)	2019-01-28
ME02954B (me)	2018-07-20
PE20181317A1 (es)	2018-08-14
CR20180311A (es)	2018-10-18
RU2018120524A (ru)	2019-12-13
JP6962915B2 (ja)	2021-11-10
KR20240029115A (ko)	2024-03-05
MX385207B (es)	2025-03-04
MA41653A (fr)	2018-01-09
IL259269B2 (en)	2024-07-01
ES2662418T3 (es)	2018-04-06
CA3005085A1 (en)	2017-05-18
RS56676B1 (sr)	2018-03-30
CO2018005915A2 (es)	2018-06-20
HRP20171949T1 (hr)	2018-01-26
KR20180083382A (ko)	2018-07-20
BR112018009714A8 (pt)	2019-02-26
CN108473563B (zh)	2022-06-14
US10544211B2 (en)	2020-01-28
RU2018120524A3 (2)	2020-09-24
US20170190769A1 (en)	2017-07-06
HUE035805T2 (en)	2018-05-28
EP3191511B1 (en)	2017-09-20
US9745372B2 (en)	2017-08-29
CN108473563A (zh)	2018-08-31
PL3191511T3 (pl)	2018-03-30
HK1248716A1 (en)	2018-10-19
WO2017081320A1 (en)	2017-05-18
SG11201803975SA (en)	2018-06-28
CY1120303T1 (el)	2019-07-10
DOP2018000122A (es)	2018-09-30
KR102641194B1 (ko)	2024-02-26
IL259269B1 (en)	2024-03-01
CA3005085C (en)	2024-09-10
JP7357038B2 (ja)	2023-10-05
GT201800095A (es)	2019-08-15
MX2018005992A (es)	2019-01-31
LT3191511T (lt)	2018-01-10
CA3234178A1 (en)	2017-05-18
NO2768984T3 (2)	2018-06-09
CL2018001291A1 (es)	2018-09-14
EP3191511A1 (en)	2017-07-19
IL310373A (en)	2024-03-01
PT3191511T (pt)	2017-11-30
SI3191511T1 (en)	2018-01-31
JP2022020666A (ja)	2022-02-01
BR112018009714A2 (en)	2018-11-21
TN2018000159A1 (en)	2019-10-04
JP2019506839A (ja)	2019-03-14
EP3266798A3 (en)	2018-03-28
AU2016352943A1 (en)	2018-06-07
DK3191511T3 (en)	2018-01-08
MD3191511T2 (ro)	2018-03-31
ECSP18042569A (es)	2018-07-31
EP3266798A2 (en)	2018-01-10
SMT201700590T1 (it)	2018-01-11
US20170267752A1 (en)	2017-09-21
IL259269A (en)	2018-07-31

Legal Events

Date	Code	Title	Description
2023-02-16	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU2016352943B2 (en)	2022-10-20	Improved TNF binders
JP7471987B2 (ja)	2024-04-22	改善された免疫グロブリン可変ドメイン
US10544216B2 (en)	2020-01-28	P2X7 receptor antagonists and agonists
TWI480051B (zh)	2015-04-11	生物化合物
RU2774823C2 (ru)	2022-06-23	Усовершенствованные агенты, связывающие tnf
HK1238660B (en)	2018-10-05	Improved tnf binders
HK1238660A1 (en)	2018-05-04	Improved tnf binders
CA2875234C (en)	2025-11-18	P2x7 receptor antagonists and agonists
HK40017968A (en)	2020-09-25	Improved serum albumin binders
HK40017968B (en)	2024-12-13	Improved serum albumin binders